The German life-science and chemicals company attributed earnings growth to a recovery of its life-science segment, cost discipline and lower spending on research and development following the ...
Its health care business showed good profitability thanks to multiple sclerosis drug Mavenclad and cancer drug Erbitux, as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback